Page 139 - 2021_04-Haematologica-web

A novel flow cytometric panel to distinguish reactive and neoplastic PDC
AA, Mascarenhas J. Blastic plasmacytoid dendritic cell neoplasm-current insights. Clin Lymphoma Myeloma Leuk. 2019;19 (9):545-554.
5. Sapienza MR, Pileri A, Derenzini E, et al. Blastic plasmacytoid dendritic cell neo- plasm: state of the art and prospects. Cancers (Basel). 2019;11(5).
6. Garnache-Ottou F, Vidal C, Biichle S, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv. 2019;3(24):4238- 4251.
7. Lyapichev KA, Sukswai N, Konoplev S, Khoury JD. Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid fea- tures and macrovacuoles. Ann Hematol. 2019;98(9):2221-2222.
8. Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12): 1055-1061.
9. Sukswai N, Aung PP, Yin CC, , et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacy- toid dendritic cell neoplasm. Am J Surg Pathol. 2019;43(10):1429-1437.
10. Comeau MR, Van der Vuurst de Vries AR,
Maliszewski CR, Galibert L. CD123bright plasmacytoid predendritic cells: progeni- tors undergoing cell fate conversion? J Immunol. 2002;169(1):75-83.
11. Osaki Y, Yokohama A, Saito A, et al. Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plas- macytoid dendritic cell neoplasm? PLoS One. 2013;8(11):e81722.
12. Petrella T, Comeau MR, Maynadie M, et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) origi- nates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26(7):852-662.
13. Khoury JD, Wang WL, Prieto VG, et al. Validation of Immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial. Clin Cancer Res. 2018;24(3):521-531.
14. Boiocchi L, Lonardi S, Vermi W, Fisogni S, Facchetti F. BDCA-2 (CD303): a highly spe- cific marker for normal and neoplastic plas- macytoid dendritic cells. Blood. 2013;122 (2):296-297.
15. Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extended diagnostic criteria for plasma- cytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-636.
16. Arcangeli S, Rotiroti MC, Bardelli M, et al.
Balance of Anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 2017;25(8):1933-1945.
17. Julia F, Dalle S, Duru G, et al. Blastic plas- macytoid dendritic cell neoplasms: clinico- immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014;38(5):673-680.
18. Jaye DL, Geigerman CM, Herling M, Eastburn K, Waller EK, Jones D. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neo- plasms. Mod Pathol. 2006;19(12):1555-1562.
19. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, et al. Acute lymphoplasmacytoid den- dritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res. 2010;34(4):438-446.
20. Huang Y, Wang Y, Chang Y, et al. Myeloid neoplasms with elevated plasmacytoid dendritic cell differentiation reflect the mat- uration process of dendritic cells. Cytometry A. 2020;97(1):61-69.
21. Brunetti L, Di Battista V, Venanzi A, et al. Blastic plasmacytoid dendritic cell neo- plasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia. 2017;31(5):1238-1240.
haematologica | 2021; 106(4)
1055